13G Filing: Partner Fund Management and Coherus Biosciences Inc. (CHRS)

Page 9 of 13

Page 9 of 13 – SEC Filing

CUSIP No. 19249H103 13G Page 9 of 13 Pages
Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the
person filing is a:
(a) [__] Broker or dealer registered under Section 15 of the Exchange Act;
(b) [__] Bank as defined in Section 3(a)(6) of the Exchange Act;
(c) [__] Insurance company as defined in Section 3(a)(19) of the Exchange Act;
(d) [__] Investment company registered under Section 8 of the Investment Company Act;
(e) [__] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [__] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
(g) [__] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h) [__] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
(i) [__] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j) [__] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If filing as
a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

Follow Coherus Biosciences Inc. (NASDAQ:CHRS)

Page 9 of 13